Eppin Pharma Inc. of Chapel Hill, North Carolina, is an emerging pharmaceutical company focused on developing a safe non-hormonal oral male contraceptive. The company was founded by Michael G. O’Rand, PhD, (Inventor and President) at the University of North Carolina at Chapel Hill, Zahed Subhan, PhD, MBA, JD, a former pharmaceutical and biotech company executive, and Jeffrey A. Handler, PhD, DABT. MBA, a board-certified toxicologist with broad experience in pharmaceutical and medical device research and development

Management Team

MIKE_ORAND2 (1)President & CEO: Michael O’Rand, Ph.D., is a retired professor in the Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, School of Medicine. Dr. O’Rand is a reproductive biologist and has more than 35 years of experience in studying mechanisms underlying human fertilization. Dr. O’Rand established the in vitro fertilization laboratory in UNC School of Medicine’s North Carolina Memorial Hospital and the first “test tube” baby in North Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed publications. Dr. O’Rand has an A.B. from the University of California at Berkeley, an M.S. from Oregon State University, Corvallis, Oregon and a Ph.D. in Biology from Temple University, Philadelphia, PA.

Jeff Handler (1)COO: Jeffrey A. Handler, Ph.D., DABT, MBA, is a Board certified toxicologist with broad experience in many areas of pharmaceutical and medical device research and development in multiple therapeutic areas, including antibacterials, therapeutic and aesthetic dermatology, stroke, Alzheimer’s disease, diabetes, urinary incontinence and rheumatoid arthritis, obtained over more than 24 years in the pharmaceutical business. He has extensive leadership and management skills within pharmaceutical R&D ranging from drug discovery through development and support of commercialized products and a track record of successful collaboration with colleagues in both scientific and commercial business areas. Dr. Handler has a Ph.D. in Pharmacology (1987) from the University of North Carolina at Chapel Hill and an MBA (2005) from Villanova University, Villanova, PA.

K_Hamil Eppin Pharma (1)Director of Laboratory Operations: Katherine G. Hamil, B.S., M.S. is a molecular biologist and biochemist with more than 30 peer-reviewd publications involving the male reproductive tract. She has 30 years of laboratory and project management experience and extensive repertoire of laboratory techniques. She has an B.S. from the University of Michigan at Ann Arbor and M.S. in Biochemistry from the University of North Carolina at Chapel Hill.

 

 

 

Scientific Advisory Board

The Scientific Advisory Board (SAB) currently has three members. Dr. O’Rand, inventor and co-founder of Eppin Pharma, serves as chair of the SAB. The SAB will contribute expertise and guidance to Eppin Pharma’s business and scientific strategies.

Laneta Dorflinger, PhD

Distinguished Scientist and Director, Contraceptive Technology Innovation, FHI360, Durham, NC 27701 USA

Areas of expertise: Contraceptive technologies, HIV prevention research, Reproductive health, Hormonal contraception

Gregory S. Kopf, PhD

Director, Research & Development, Global Health, Population & Nutrition, Contraceptive Technology Innovation, FHI360, Durham, NC 27701 USA

Areas of expertise: Reproductive health, Industry experience in women’s health (Wyeth), Contraceptive technology, reproductive (sperm and testis) biology.

John K. Amory MD, MPH

Professor of Medicine, Section Head, General Internal Medicine
University of Washington, Seattle WA

Areas of expertise: Board certified in internal medicine, Men’s reproductive health, Clinical evaluation of male contraceptives, Reproductive biology